Neoadjuvant therapy in pancreatic cancer

Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111-2497, USA.
Cancer Investigation (Impact Factor: 2.06). 07/2007; 25(4):267-73. DOI: 10.1080/07357900701206356
Source: PubMed

ABSTRACT Pancreatic cancer is the fourth leading cause of cancer deaths in the United States. Surgical resection offers the only hope of cure, though the addition of chemoradiation in the adjuvant setting has been shown to improve survival over surgery alone. Many patients are unable to receive adjuvant therapy due to prolonged postoperative recovery. For this reason, administration of chemoradiation preoperatively (neoadjuvant) has been proposed as an alternative to postoperative treatment. In patients with resectable disease, neoadjuvant therapy results in similar survivals compared to postoperative therapy, with a greater proportion of patients able to complete treatment. For selected patients with borderline or unresectable disease, neoadjuvant therapy offers the potential for tumor downstaging and increasing the likelihood of a margin-negative resection. This article reviews the use of neoadjuvant therapy in the treatment of pancreatic cancer.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Pancreatic cancer, a lethal malignancy is difficult to diagnose and is associated with poor prognosis due to distal dissemination of the cancer to organs such as the liver, spleen and gastrointestinal tract. Epidermal growth factor receptor (EGFR), a member of ErbB family of growth factor receptors, is over-expressed in pancreatic cancer and is an important indicator of poor prognosis and therapeutic outcomes. Cetyltriethylammonium bromide (CTAB)-modified positively-charged poly(ethylene oxide)-poly(epsilon-caprolactone) (PEO-PCL) nanoparticles loaded with both EGFR-silencing siRNA and paclitaxel (PTX) were prepared and characterized by determining particle size and surface charge found to be approximately 260 nm and 10 mV respectively. When 1 nM siRNA was loaded on 2 mg of CTAB-modified PEO-PCL nanoparticles, the loading capacity and efficiency were 6.5 μg/2 mg and 97%, respectively. Human pancreatic adenocarcinoma (Panc-1) cells were incubated for 3 hours with PEO-modified PCL nanoparticles loaded with siGLO siRNA and OregonGreen®-labeled PTX and viewed under a fluorescence microscope to confirm nanoparticle uptake and distribution in the cells. The baseline EGFR expression in Panc-1 cells was confirmed by Western blot and immunocytometric analysis. The EGFR silencing efficacy studies using aqueous solution and nanoparticle formulations was examined with RT-PCR and Western blot analysis. These studies were carried out by extracting RNA and protein from Panc-1 cells treated with EGFR silencing siRNA- and scrambled siRNA-loaded CTAB-modified-PEO-PCL nanoparticles. For the Western blot and PCR EGFR band intensity was the least for protein extracted from cells treated with EGFR siRNA loaded nanoparticles compared to band intensity from protein extracted from both untreated cells and cells treated with scrambled siRNA loaded nanoparticles. The results of an MTS assay showed that PTX loaded CTAB-modified-PEO-PCL nanoparticles had a 3-fold lower IC50 value of 100nM compared to PTX in solutions, which had an IC50 of 300nM. Similarly siRNA loaded CTAB-modified PEO-PCL nanoparticles showed a greater reduction in percent cell viability compared to siRNA in solution. And finally combination of EGFR siRNA + PTX loaded CTAB-modified PEO-PCL nanoparticles showed greater reduction in percent cell viability compared to using either alone or PTX loaded nanoparticles, scrambled siRNA loaded nanoparticles and combination of scrambled siRNA + PTX loaded nanoparticles. Lastly, both quantitative and qualitative apoptosis studies were carried out using treated and untreated Panc-1 cells. Caspase 3/7 assay was performed to quantitatively determine that maximum apoptosis occurs in cells incubated with a combination of EGFR siRNA and PTX loaded nanoparticles. Qualitative TUNEL assay was performed to evaluate the enhancement in apoptotic cell death due to combination therapy. In comparison to the other treatments combination of EGFR siRNA + PTX loaded nanoparticles showed the most apoptotic cells based on the brown stained nuclei.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Patients with borderline resectable pancreatic cancer are at high risk of having positive surgical margins due to involvement of the tumor with adjacent vasculature. This article reviews the management of this subset of pancreatic cancer patients. The authors review the current definitions of borderline resectable pancreatic cancer and how it is diagnosed and staged. The history, current approaches, and future directions in neoadjuvant therapy for borderline resectable pancreatic cancer are also reviewed with emphasis on various chemotherapy regimens that have been used. The application of intensity-modulated radiation therapy and image-guided radiation therapy that accounts for respiratory motion to targeting the gross tumor volume in the pancreas are discussed, and the promise of integrating targeted therapies in neoadjuvant treatment programs is highlighted. The use of neoadjuvant treatment programs that employ gemcitabine-based chemotherapy regimens followed by chemoradiation increases the likelihood of subsequent margin-negative resection in borderline resectable pancreatic cancer. There has been progress in the imaging, staging, surgical technique, and the use of chemotherapy and chemoradiotherapy in the management of borderline resectable pancreatic cancer. Patients can benefit from multidisciplinary management at high-volume pancreatic cancer treatment centers.
    Cancer control: journal of the Moffitt Cancer Center 11/2008; 15(4):295-307. · 2.66 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Pancreatic cancer (PC) represents one of the greatest oncological challenges of our century, due to its high mortality and incidence. A group of Spanish experts in PC treatment reviewed data available on different therapeutic combinations and established consensus on what would be the best strategy in PC management, depending on the stage of the disease. Surgery with complete resection may produce 5-year survival rates of 18–24%, but definitive control is still precarious. In the absence of consensus, the best evidence suggests that adjuvant chemotherapy with gemcitabine for 6 months using the CONKO-001 regime is the treatment of choice after resection of PC for patients with acceptable functional status. This group recommends chemoradiotherapy (CT-RT) in patients with factors for poor loco-regional prognosis. However, chemotherapy is an option for the treatment of locally advanced PC in patients with good general status and in the absence of metastatic disease the recommended treatment is CT-RT followed by gemcitabine-based chemotherapy. A period of chemotherapy followed by consolidation CT-RT may be appropriate, as it allows selection of patients with locally advanced disease who may benefit most from combined treatment. Erlotinib combined with gemcitabine shows significant survival improvement in PC and must be considered an option in the first-line treatment of advanced and metastatic PC. The gemcitabine-erlotinib combination is proposed as the standard treatment for metastatic PC in patients with PS≥2. In patients with PS<2, gemcitabine-erlotinib is recommended as the first-line treatment option, supported by a maximum degree of evidence, without ruling out other options, such as gemcitabine-oxaliplatin, gemcitabine-capecitabine or gemcitabine alone.
    Clinical and Translational Oncology 05/2009; 11(5):290-301. DOI:10.1007/s12094-009-0357-3 · 1.60 Impact Factor